Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

Published 11/04/2024, 13:46
Updated 11/04/2024, 15:10
© Reuters.  Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

Verve Therapeutics Inc (NASDAQ: VERV)

  • On April 2, Verve Therapeutics announced an update from the Heart-1 Phase 1b trial of VERVE-101. VERVE-101 is being evaluated in patients with a genetic condition that leads to high cholesterol levels, which raises the risk of heart disease. The treatment is supposed to permanently turn off a protein called PCSK9, which helps reduce blood cholesterol levels. The company’s stock fell around 44% over the past month and has a 52-week low of $7.36 .
  • RSI Value: 25.88
  • VERV Price Action: Shares of Verve Therapeutics fell 8.5% to close at $8.01 on Wednesday.
UnitedHealth Group Inc
  • On April 10, TD Cowen analyst Gary Taylor maintained UnitedHealth with a Buy and lowered the price target from $607 to $546.. The company’s stock fell around 8% over the past month. It has a 52-week low of $445.68.
  • RSI Value: 27.67
  • UNH Price Action: Shares of UnitedHealth fell 2.1% to close at $450.05 on Wednesday.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
Gilead Sciences, Inc.
  • On April 8, Gilead Sciences said it will release its first quarter 2024 financial results and guidance on Thursday, April 25, 2024, after the closing bell.. The company’s stock fell around 10% over the past month and has a 52-week low of $68.06.
  • RSI Value: 27.43
  • GILD Price Action: Shares of Gilead Sciences fell 2.6% to close at $68.12 on Wednesday.

Check This Out: How To Earn $500 A Month From Citigroup Stock Ahead Of Q1 Earnings Report

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.